β¨ Medicines Notices
17 FEBRUARY 2011 NEW ZEALAND GAZETTE, No. 16
361
Suspension of Consent to the Distribution of Medicines
Pursuant to section 35(1)(a) of the Medicines Act 1981, the Minister of Health hereby suspends consent to the distribution in New Zealand of the following medicines:
Schedule
Product: Avandia
Active Ingredient: Rosiglitazone maleate 1.33mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Product: Avandia
Active Ingredient: Rosiglitazone maleate 2.65mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Product: Avandia
Active Ingredient: Rosiglitazone maleate 5.3mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Product: Avandia
Active Ingredient: Rosiglitazone maleate 10.6mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Product: Avandamet
Active Ingredients: Rosiglitazone maleate 1.33mg
Metformin hydrochloride 500mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Product: Avandamet
Active Ingredients: Rosiglitazone maleate 2.65mg
Metformin hydrochloride 500mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Product: Avandamet
Active Ingredients: Rosiglitazone maleate 2.65mg
Metformin hydrochloride 1000mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Product: Avandamet
Active Ingredients: Rosiglitazone maleate 5.3mg
Metformin hydrochloride 500mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Product: Avandamet
Active Ingredients: Rosiglitazone maleate 5.3mg
Metformin hydrochloride 1000mg
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
The above notice comes into force on 29 April 2011.
Note: This notice will remain in force until such time as the Minister of Health is satisfied that the benefits of using these medicines outweighs the risks of their use in a specified population group. In that event, a further notice would be issued in the New Zealand Gazette to revoke this suspension.
Dated this 3rd day of February 2011.
BARBARA PHILLIPS, Acting Deputy Director-General, Population Health Directorate, Ministry of Health (pursuant to delegation given by the Minister of Health on 20 December 2001 and the Director-General of Health on 18 January 2002).
go1000
Classification of Medicines
Pursuant to section 106(1) of the Medicines Act 1981,
I, Barbara Phillips, Acting Deputy Director-General, Population Health Directorate, Ministry of Health, acting under delegated authority, hereby declare the following:
-
The medicines listed in Schedule 1 to this notice are classified as prescription medicines.
-
The medicines listed in Schedule 3 to this notice are classified as pharmacy-only medicines.
Next Page →
β¨ LLM interpretation of page content
π₯ Suspension of Consent to the Distribution of Medicines
π₯ Health & Social Welfare3 February 2011
Medicines Act, Suspension, Avandia, Avandamet, Rosiglitazone, GlaxoSmithKline
- Barbara Phillips, Acting Deputy Director-General, Population Health Directorate, Ministry of Health
π₯ Classification of Medicines
π₯ Health & Social WelfareMedicines Act, Classification, Prescription medicines, Pharmacy-only medicines
- Barbara Phillips, Acting Deputy Director-General, Population Health Directorate, Ministry of Health
NZ Gazette 2011, No 16